203 related articles for article (PubMed ID: 17083507)
1. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy.
Peerlinck K; Hermans C
Haemophilia; 2006 Nov; 12(6):579-90. PubMed ID: 17083507
[TBL] [Abstract][Full Text] [Related]
2. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
Lusher JM
Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
[TBL] [Abstract][Full Text] [Related]
3. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII.
Singleton E; Smith J; Kavanagh M; Nolan B; White B
Thromb Haemost; 2007 Dec; 98(6):1188-92. PubMed ID: 18064312
[TBL] [Abstract][Full Text] [Related]
4. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
Bacon CL; Singleton E; Brady B; White B; Nolan B; Gilmore RM; Ryan C; Keohane C; Jenkins PV; O'Donnell JS
Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
[TBL] [Abstract][Full Text] [Related]
5. The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors.
Gomperts ED
Haemophilia; 2006 Nov; 12(6):573-8. PubMed ID: 17083506
[TBL] [Abstract][Full Text] [Related]
6. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A.
Valentino LA; Recht M; Dipaola J; Shapiro AD; Pipe SW; Ewing N; Urgo J; Bullock T; Simmons M; Deguzman C
Haemophilia; 2009 May; 15(3):718-26. PubMed ID: 19298383
[TBL] [Abstract][Full Text] [Related]
7. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
Martinowitz U; Luboshitz J; Bashari D; Ravid B; Gorina E; Regan L; Stass H; Lubetsky A
Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
[TBL] [Abstract][Full Text] [Related]
8. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study.
Strauss T; Lubetsky A; Ravid B; Bashari D; Luboshitz J; Lalezari S; Misgav M; Martinowitz U; Kenet G
Haemophilia; 2011 Jul; 17(4):625-9. PubMed ID: 21299743
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
Rea C; Dunkerley A; Sørensen B; Rangarajan S
Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
[TBL] [Abstract][Full Text] [Related]
10. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
Rubinger M; Lillicrap D; Rivard GE; Teitel J; Carcao M; Hensman C; Walker I;
Haemophilia; 2008 Mar; 14(2):281-6. PubMed ID: 18194308
[TBL] [Abstract][Full Text] [Related]
11. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
[TBL] [Abstract][Full Text] [Related]
12. Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non-interventional study.
Rivard GE; Rothschild C; Toll T; Achilles K
Haemophilia; 2013 May; 19(3):449-55. PubMed ID: 23510123
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
Reipert BM; van Helden PM; Schwarz HP; Hausl C
Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
[TBL] [Abstract][Full Text] [Related]
14. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors.
Singer ST; Addiego JE; Reason DC; Lucas AH
Thromb Haemost; 1996 Jul; 76(1):17-22. PubMed ID: 8819245
[TBL] [Abstract][Full Text] [Related]
15. Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.
Volkers P; Hanschmann KM; Calvez T; Chambost H; Collins PW; Demiguel V; Hart DP; Hay CRM; Goudemand J; Ljung R; Palmer BP; Santagostino E; van Hardeveld EM; van den Berg M; Keller-Stanislawski B
Haemophilia; 2019 May; 25(3):398-407. PubMed ID: 31066174
[TBL] [Abstract][Full Text] [Related]
16. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.
Chalmers EA; Brown SA; Keeling D; Liesner R; Richards M; Stirling D; Thomas A; Vidler V; Williams MD; Young D;
Haemophilia; 2007 Mar; 13(2):149-55. PubMed ID: 17286767
[TBL] [Abstract][Full Text] [Related]
17. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy.
Field JJ; Fenske TS; Blinder MA
Haemophilia; 2007 Jan; 13(1):46-50. PubMed ID: 17212724
[TBL] [Abstract][Full Text] [Related]
18. Incidence of inhibitors in haemophiliacs. A review of the literature.
Scharrer I; Neutzling O
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):753-8. PubMed ID: 8292725
[TBL] [Abstract][Full Text] [Related]
19. Immunological aspects of inhibitor development.
Reding MT
Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
[TBL] [Abstract][Full Text] [Related]
20. The epidemiology of factor VIII inhibitors.
Hay CR
Haemophilia; 2006 Dec; 12 Suppl 6():23-8; discussion 28-9. PubMed ID: 17123390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]